BioNTech and InstaDeep to Host Second AI Day on October 1, 2025
PorAinvest
martes, 23 de septiembre de 2025, 6:46 am ET1 min de lectura
BNTX--
The AI Day event will be accessible through a live webcast and will be available on BioNTech's Investor Relations website for one year following the event. The recording will be archived on the company's website for participants to review at their convenience. This event marks a significant milestone in BioNTech's continued focus on AI development, following their acquisition of InstaDeep Ltd. [1]
BioNTech's AI strategy is aimed at leveraging artificial intelligence to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. By integrating AI into its research and development processes, BioNTech aims to enhance the efficiency and effectiveness of its pipeline.
The event will provide an overview of BioNTech’s AI strategy and capabilities, as well as the application of AI in the company's pipeline and internal processes. The live webcast of the event will be available via this link. Participants may also access the slides and a recording of the event via the “Events & Presentations” page in the Investor Relations section of BioNTech’s website at . The recording will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year thereafter.
BioNTech, a global immunotherapy company, will host its second AI Day on October 1, 2025, in London. The event will showcase the company's AI strategy and capabilities, as well as its application in the pipeline and internal processes. The live webcast will be available on BioNTech's website, and the recording will be archived for one year. The event is part of the company's Innovation Series.
BioNTech SE (NASDAQ: BNTX), a global biopharmaceutical company specializing in immunotherapy, has announced its second AI Day event as part of its Innovation Series. The event is scheduled for October 1, 2025, at 9:00 AM EDT in London. This event will provide insights into BioNTech's AI strategy and its applications in the company's pipeline and internal processes.The AI Day event will be accessible through a live webcast and will be available on BioNTech's Investor Relations website for one year following the event. The recording will be archived on the company's website for participants to review at their convenience. This event marks a significant milestone in BioNTech's continued focus on AI development, following their acquisition of InstaDeep Ltd. [1]
BioNTech's AI strategy is aimed at leveraging artificial intelligence to accelerate the development of novel biopharmaceuticals. The company's portfolio includes mRNA cancer immunotherapies, next-generation immunomodulators, and targeted therapies such as antibody-drug conjugates (ADCs) and innovative chimeric antigen receptor (CAR) T cell therapies. By integrating AI into its research and development processes, BioNTech aims to enhance the efficiency and effectiveness of its pipeline.
The event will provide an overview of BioNTech’s AI strategy and capabilities, as well as the application of AI in the company's pipeline and internal processes. The live webcast of the event will be available via this link. Participants may also access the slides and a recording of the event via the “Events & Presentations” page in the Investor Relations section of BioNTech’s website at . The recording will be available shortly after the event’s conclusion and archived on BioNTech’s website for one year thereafter.

Divulgación editorial y transparencia de la IA: Ainvest News utiliza tecnología avanzada de Modelos de Lenguaje Largo (LLM) para sintetizar y analizar datos de mercado en tiempo real. Para garantizar los más altos estándares de integridad, cada artículo se somete a un riguroso proceso de verificación con participación humana.
Mientras la IA asiste en el procesamiento de datos y la redacción inicial, un miembro editorial profesional de Ainvest revisa, verifica y aprueba de forma independiente todo el contenido para garantizar su precisión y cumplimiento con los estándares editoriales de Ainvest Fintech Inc. Esta supervisión humana está diseñada para mitigar las alucinaciones de la IA y garantizar el contexto financiero.
Advertencia sobre inversiones: Este contenido se proporciona únicamente con fines informativos y no constituye asesoramiento profesional de inversión, legal o financiero. Los mercados conllevan riesgos inherentes. Se recomienda a los usuarios que realicen una investigación independiente o consulten a un asesor financiero certificado antes de tomar cualquier decisión. Ainvest Fintech Inc. se exime de toda responsabilidad por las acciones tomadas con base en esta información. ¿Encontró un error? Reportar un problema

Comentarios
Aún no hay comentarios